Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Oncogene ◽  
2019 ◽  
Vol 39 (9) ◽  
pp. 1846-1859 ◽  
Author(s):  
Ying Jin ◽  
Hua Bao ◽  
Xiuning Le ◽  
Xiaojun Fan ◽  
Ming Tang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Genomic Evolution ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Lung Cancer Patients ◽  
Tki Treatment

Analysis of the EGFR mutations in non-small cell lung cancer patients after EGFR-TKI treatment.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e18065-e18065
Author(s):  
H. Yamaguchi ◽  
T. Ikeda ◽  
N. Tomonaga ◽  
H. Nakano ◽  
T. Kitazaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Tki Treatment ◽  
Egfr Tki

Determination of plasma EGFR mutations from non-small cell lung cancer patients at Bach Mai Hospital.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e13121-e13121
Author(s):  
Cam Phuong Pham ◽  
Khoa Trong Mai ◽  
Nguyen Thuan Loi ◽  
NGO Thi Thu Hien ◽  
Quynh Thi Thuy Vo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
T790m Mutation ◽  
Lung Cancer Patients

e13121 Background: Lung cancer patients with mutations in the epidermal growth factor receptor (EGFR) are primary candidates for EGFR-targeted therapy. Reliable analyses of such mutations have previously been possible only in tumor tissue. Here, we demonstrate that mutations can be detected in plasma samples of non-small cell lung cancer patients at Bach Mai Hospital and relation of different variables to the frequency of EGFR mutations. Methods: 193 patients with non-small cell lung cancer were identified with EGFR mutation by cobas EGFR Mutation Test v2 kit (Roche Diagnostics, USA), evaluating the EGFR mutation status with different variables. Results: The EGFR mutation rate was 43%, common in patients with adenocarcinoma, female, non-smoking, late stage disease. The rate of EGFR T790M mutation was 36.1%. Among 78 patients who was previous treated TKIs, EGFR mutation rate was 73.1% and the rate of EGFR T790M mutation was 50.8% at the time of progression. The concordance of EGFR mutation from plasma sample with tissue sample was 81%. Conclusions: EGFR mutation in plasma sample results was not different from those in tissue samples and similar with result of studies in Vietnam and worldwide.

Sign in / Sign up

Export Citation Format

Share Document